Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04778046 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pulmonary Hypertension SOLAR

Study acronym: PH SOLAR
StatusRecruiting
PhasePhase 2
Started2023-11-08
View on ClinicalTrials.gov ↗

Amendment history

2026-02-23
Study Status, Oversight v19
Primary completion date2025-12-30→2027-07-31
Completion date2025-12-30→2028-07-31
2025-10-17
Study Status, Contacts/Locations v18
Study sitescontacts updated at 1 of 1 site
2025-01-17
Study Status, Oversight, Contacts/Locations v17
Primary completion date2024-12-30→2025-12-30
Completion date2024-12-30→2025-12-30
Study sitescontacts updated at 1 of 1 site
2024-07-15
Study Status, Outcome Measures v16
Re-verified, no change to tracked fields
2024-01-16
Study Status v15
Primary completion date2023-12-30→2024-12-30
Completion date2023-12-30→2024-12-30
Show 14 earlier versions
2023-12-15
Study Status v14
Start dateestimated 2023-11-15→confirmed 2023-11-08
2023-10-20
Study Status v13
Start date2023-09-15→2023-11-15
2023-06-23
Study Status v12
Primary completion date2023-08-30→2023-12-30
Completion date2023-08-30→2023-12-30
Start date2023-05-15→2023-09-15
2023-04-10
Study Status v11
Start date2023-02-15→2023-05-15
2023-01-23
Study Status v10
Start date2022-12-15→2023-02-15
2022-10-05
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v9
Trial statusNot Yet Recruiting→Recruiting
Study sitesdetails revised at 1 of 1 site
2022-10-04
Study Status v8
Start date2022-08-15→2022-12-15
2022-05-03
Study Status v7
Primary completion date2023-10-30→2023-08-30
Completion date2023-10-30→2023-08-30
Start date2022-02-15→2022-08-15
2022-01-14
Study Status v6
Start date2021-12-01→2022-02-15
2021-10-27
Study Status v5
Start date2021-10-01→2021-12-01
2021-07-27
Study Status v4
Primary completion date2023-06-30→2023-10-30
Completion date2023-06-30→2023-10-30
Start date2021-07-01→2021-10-01
2021-05-25
Study Status v3
Start date2021-05-01→2021-07-01
2021-03-11
Study Status, Study Description, Arms and Interventions, Eligibility v2
Study description-4 characters
[...] nder phenotypes when treated with PAH-specific therapies. In our preliminary studies of subjects treated with Tyvaso, The st [...]
2021-03-02
Study Status, Study Description, Study Design v1
Study description-234 characters
[...] ial responders vs non-responders to PAH-specific therapies. OurThe central hypothesis is that similar mechanisms and pathways underlie pulmonary vascular remodeling in IPF-PH, COPD-PH, and PAH. However, only a subset of Group 3 PH patients disp [...] In our preliminary studies of subjects treated with Tyvaso, weThe havestudy team has observed distinct 129Xe MRI signatures at baseline and with [...] function. Consistent with this, recent studies using single-cell RNA sequencing (scRNAseq) of the pulmonary vasculature [...] ve demonstrated changes consistent with vascular remodeling. By taking advantage of the act [...]
2021-02-26
Original filing
Bastiaan Driehuys
11 trials monitored
See all monitored trials
Hypertension
1,786 trials monitored
See 77 trials at risk
COPD
1,057 trials monitored
See 28 trials at risk
The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic "ground truth" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant tissue from patients who have undergone a lung transplant. This signature could be validated in a cohort of patients with Group 3 PH in future studies.
Trial Details
NCT Number NCT04778046
Lead Sponsor Bastiaan Driehuys
Conditions Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Enrollment 30 participants
Start Date 2023-11-08
Primary Completion 2027-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-24